INTER PHARMA PUBLIC COMPANY LIMITEDSET: IP🇹🇭 TH

Business Operation · 2025

Corporate Information

Company Name

INTER PHARMA PUBLIC COMPANY LIMITED

Telephone

0-2634-0225

Website

www.interpharma.co.th

Email

www.ir@interpharma.co.th

Dividend Policy

Dividend Policy

The Company has the policy to pay dividends of not less than 50% of its net profit after income tax and to maintain all types of reserves as required by laws, considering the separate financial statements of the Company. The consideration of a dividend payment depends on cash flow, sufficiency of working capital in business operations, an investment plan, loan repayment, and the terms and conditions of various agreements to which the Company is bound, including legal limitations and other necessities and suitability in the future.

However, the Board of Directors' resolution approving the dividend payment must be presented for approval at the shareholders' meeting, except for the interim dividend payment. The Board of Directors has the authority to approve the dividend payment from time to time when the Company has sufficient profits to do so. This must be reported to the next shareholders' meeting.

Historical Dividend Payments

This YearLast Year2 Years Ago3 Years Ago4 Years AgoMetricDescription
0.200.140.360Net profit per share (Baht : Share)Net profit per share (baht : share)
0.0700.030.180Dividend per share (Baht : Share)Dividend per share (baht : share)
00800Dividend stock ratio (Number of original shares: dividend shares)Ratio of stock dividend payment (existing share : stock dividend)
000.3100Dividend share value per share (Baht : Share)Value of stock dividend per share (baht : share)
0.0700.350.180Total dividend payment value (Baht : Share)Total dividend payment (baht : share)
60062.1269.440Dividend payout ratio to net profit (%)Dividend payout ratio compared to net profit (%)

Major Shareholders

Major Shareholders

No.NameShares% Shares
24,651MR. TRINNAWAT THANITNITHIPHAN193,562,06731.98
24,652INNOBIC LL HOLDING COMPANY LIMITED121,078,75020
24,653MR. PILIYARUTCH PHATRAKITKASEM16,629,5502.75
24,654MR. WITTAYA THEPNIMITR12,838,7962.12
24,655MR. POWWIT KLINPRATOOM7,810,0001.29
24,656MR. THAMRONGCHAI EAKAMORNWONG7,796,3481.29
24,657MR. MONCHAI LEESIRIKUL7,263,7501.2
24,658MISS PIMPATRA SUPHATCHARAWONG5,812,5000.96
24,659MISS PORNPHEN DECHWILAISRI4,874,9640.81
24,660MR. KRITAPAS JIRAYANGYEAN4,761,2500.79
24,661UOB KAY HIAN PRIVATE LIMITED4,479,8620.74
24,662MISS KRITTAYA BOONYAMANOND3,706,6250.61
24,663MR. SOMSAK JEANJARUSPONG3,522,2000.58
24,664MRS. KANOKPHAN TANYASIRI3,200,0000.53
24,665MR. VICHAPHAN HEMRUNGROJN3,093,8000.51

Business Strategies Overview

Chairman's Message

Dear Shareholders,

Inter Pharma Public Company Limited (the “Company”) conducts its business in accordance with the principles of good corporate governance while pursuing sustainable business development. The Company remains committed to operating with due regard for social and environmental responsibilities, with the aim of achieving stable and sustainable long-term growth and strengthening confidence among shareholders, investors, and all stakeholders.

In 2025, the Company operated amid a challenging business environment characterized by economic volatility, intensified competition, and evolving regulatory requirements in the pharmaceutical and healthcare product industries. Nevertheless, the Board of Directors and the management team have worked closely together to carefully determine the Company’s strategic direction and drive the implementation of key initiatives to enhance competitiveness and establish a solid foundation for sustainable long-term growth.

The Company places strong emphasis on the development of high-quality and differentiated products. Its focus remains on pharmaceutical and healthcare products supported by scientific evidence and designed to address specific healthcare needs. At the same time, the Company maintains strict quality control throughout every stage of the production process in accordance with Good Manufacturing Practice (GMP) standards, thereby reinforcing confidence among consumers and all stakeholders.

The Company continues to systematically expand its distribution channels both domestically and internationally through its subsidiaries and strategic business partners, enabling broader access to end consumers. The Company has also begun laying the groundwork for international business expansion by strengthening capabilities in areas such as human resource development, regulatory knowledge, and product registration processes. These initiatives represent important steps toward expanding the Company’s customer base and creating future business opportunities.

In addition, the Company applied to participate in the Listed Company Value Enhancement Program (JUMP+), organized by the Stock Exchange of Thailand, to foster sustainable growth and enhance long-term value for the Company and Shareholders.

On behalf of the Board of Directors and the management team, we would like to express our sincere appreciation to all stakeholders for their continued trust and support. The Board and management remain firmly committed to conducting the Company’s business with prudence, transparency, and accountability, with the objective of continuously creating value and delivering appropriate returns to shareholders and all stakeholders.

Vision

Be a leader in inventing and presenting our various range of health products with efficiency and safety for prevention and treatment of diseases, longer life, and anti-aging.

Objectives

To achieve the Company’s vision, the Company’s mission has been defined as 6 items as follows:

  1. Outstanding and diverse range of services and products

  2. Continuous research and product development

  3. International level of access to products and services

  4. Highly qualified and efficient personnel

  5. Social and environmental responsibilities

  6. Organization of good governance

Goals

The Company operates the business in the integrated development, research, production, and distribution of healthcare products for disease prevention, treatment, and anti-aging for both humans and companion animals, consisting of pharmaceuticals, nutraceuticals, cosmeceuticals, healthy foods, and medical devices for both human health and animal health under the concept of "VALUE YOUR LIFE" with the belief that the value of life is the good health and longevity with quality. This concept has been reflected in the Company's products to provide consumers with a healthy body and a balance in the body's system. The Company pays attention to every detail in the selection process to ensure that the Company's products are of excellent quality. The invention and presentation of biotechnology-based health products are for the prevention of diseases, to have a longer life, and for anti-aging.

Under the trademark "INTERPHARMA" the Company has set a goal within 5 years to grow into a leading Company in offering health products and shall expand distribution channels and market in the country and overseas to allow the target customers easy access to the products, be able to recognize the Company's trademark, and provide consumers with good health. In addition, the Company shall improve its internal system to increase efficiency and speed of work. It shall maintain a good relationship with partners and participate in helping, developing society, and taking environmental responsibility for long-term sustainability.

Business Strategies

Inter Pharma Public Company Limited operates its business under a strategy focused on sustainable growth alongside the enhancement of long-term competitiveness. The Company’s key strategic directions are as follows:

1. Value-Added and Differentiated Product Development Strategy

The Company places strong emphasis on research and development of pharmaceutical products, healthcare products, and dietary supplements that are of high quality, supported by scientific evidence, and specifically designed to address particular health conditions or therapeutic areas. This approach enables the Company to differentiate its products from general offerings in the market and effectively respond to consumers’ needs.

2. Quality Control and Manufacturing Standards Strategy

The Company leverages its in-house manufacturing facilities to ensure strict quality control at every stage of the production process. All operations are conducted in compliance with Good Manufacturing Practice (GMP) and other relevant standards to ensure consistent product quality, efficacy, and safety in accordance with the Company’s established requirements.

3. Comprehensive Distribution Channel Expansion and Management Strategy

The Company is committed to developing both offline and online distribution channels to comprehensively cover target customer groups, including pharmacies, hospitals, clinics, e-commerce platforms, as well as utilizing the network of its subsidiaries to directly reach end consumers. This integrated distribution approach enhances product accessibility and strengthens the Company’s competitive advantage.

4. Growth Through Investment and Synergy Within the Group

The Company pursues growth through investments in subsidiaries and associated companies operating in the healthcare and pharmaceutical sectors. This strategy aims to create synergy across manufacturing, marketing, and distribution functions, while enhancing the overall operational capabilities and value creation of the Group.

5. Brand Building and Long-Term Customer Relationship Strategy

The Company prioritizes transparent, accurate, and verifiable communication of product benefits in order to build consumer trust. This approach supports repeat purchases and fosters long-term brand loyalty.

6. Systematic International Market Expansion Strategy

The Company is in the process of establishing a foundation for international operations, with emphasis on personnel development, regulatory knowledge related to product registration, and compliance with country-specific regulations. In parallel, the Company is building strategic business partnerships to support future expansion into neighboring countries and other regions.

7. Risk Management and Sustainable Growth Strategy

The Company emphasizes effective management of operational, financial, and regulatory risks, while conducting its business in accordance with good corporate governance principles. This approach ensures stable and sustainable growth and creates long-term value for all stakeholders.

Other Information

NameDescription
Business Overview

Business Structure

Inter Pharma Public Company Limited and its subsidiaries operate a business focused on the development, research, and distribution of health products for prevention, treatment, and anti-aging for both humans and pets. The company has a fully integrated business structure covering the entire value chain, from upstream to downstream operations. The Group operates two pharmaceutical manufacturing facilities, which serve as key drivers of its growth.

The first facility, located in Ayutthaya Province, specializes in the production of high-quality ophthalmic solutions. It is currently undergoing an upgrade to meet European Union (EU) standards in order to support international market expansion and contract manufacturing at a global level.

The second facility, Modern Pharma Co., Ltd., located in Samut Prakan Province, has been fully renovated and modernized. It has gained strong trust from business partners and serves as an OEM manufacturer for a wide range of products, including inhalants, dietary supplements, and cosmeceuticals for leading brands.

On the downstream side, the Company operates a retail pharmacy business under the brand “LAB Pharmacy” and Nakornpat Inter Hospital. Both businesses have undergone renovation and service enhancements to ensure modern, comprehensive, and high-quality healthcare services.

In addition, the Company continues to focus on long-term growth through medical innovation. Key initiatives include the development of gene therapy for Parkinson’s disease in collaboration with academic institutions in Japan, as well as the development of innovative ophthalmic solutions for the treatment of myopia and hyperopia.

Nature of Business Operations

The Company and its subsidiaries operate across six business segments as follows:

1. Pharmaceuticals
This segment comprises therapeutic products for the treatment of various diseases, including those related to the gastrointestinal and respiratory systems, diabetes, musculoskeletal disorders, pain management, and general infectious diseases.

2. Wellness and Anti-Aging Products
This segment includes non-pharmaceutical products designed to promote overall health and longevity. These products focus on maintaining internal balance and are commonly referred to as nutraceuticals.

3. Companion Animal Health Products
This segment covers a comprehensive range of products for pets, including nutraceuticals, medicated shampoos for dermatological conditions, cosmeceuticals, veterinary products, vaccines, pheromone products, pet food, and absorbent pads.

4. Medical Device Distribution Business
The Group engages in the distribution of medical devices and equipment, including leasing and maintenance services. In addition, the Group provides rehabilitation medicine services.

5. Pharmacy Retail Business
The Group operates retail pharmacies under the brand “LAB Pharmacy,” offering pharmaceutical products, cosmeceuticals, and medical supplies to domestic customers. Currently, the Group operates a total of 50 branches.

6. Hospital Business
The Group operates a private hospital, “Nakornpat Inter Hospital,” which is classified as a medium-sized general hospital with a capacity of 59 beds.

Progress of the Gene Therapy Project

The Company has invested in a gene therapy business, an advanced therapeutic medicinal product (ATMP) innovation from Japan, with the objective of developing treatments for major diseases, such as Parkinson’s disease. This project represents a research collaboration between Thailand and Japan. Preliminary results from six cases in Japan have demonstrated favorable outcomes with no significant adverse effects observed. The project has received research funding support from the Thai government, along with collaborations with leading medical institutions in Thailand, including Siriraj Hospital, King Chulalongkorn Memorial Hospital, and Ramathibodi Hospital.

Progress of the Ophthalmic Drug Development Project

The Company has been granted exclusive distribution rights for an innovative ophthalmic product, including eye drops for presbyopia. This product, YUVEZZI, has been approved by the U.S. FDA as the second of its kind globally. It demonstrates strong efficacy with a favorable safety profile and minimal side effects. The Company plans to import, register, and distribute this product in Thailand.

Material Changes & Developments

Material Changes & Developments

YearDescription
2,023

On February 27, 2023, the Board of Directors Meeting No. 1/2023 approved the appointment of Dr. Yuttana Suwannachot to the position of Director of the Company in replacement of Mr. Terdkiat Prommool.

On April 27, 2023, the 2023 Annual General Meeting of Shareholders resolved to approve important matters as follows:

  • Approved the Company pay a dividend to shareholders at a rate of 0.18 Baht per share.

  • Approved the issuance and offering of warrants to purchase ordinary shares of Company No. 2 ("IP-W2") be offered free of charge and allocated proportionately to existing shareholders, 93,130,131 units.

  • Approved the capital decrease of 19,419,979.50 Baht by canceling 38,839,959 shares of unpaid-up ordinary shares.

  • Approved the capital increase of the Company 46,565,065.50 Baht by issuing 93,130,131 shares to allocate reserve for exercising the rights of the warrants to purchase ordinary shares of the Company No. 2.

  • Approved the allocation of not more than 93,130,131to allocate reserve for exercising the rights of the warrants to purchase ordinary shares of the Company No. 2

  • Approved the amending a total of 6 clauses in the Company's Articles of Association, namely Article 29, Article 35, Article 38, Article 39, Article 51, and Article 57. These amendments are necessary to comply with the Public Limited Companies Act B.E. 2535.

  • Approved the amendment of the Company's Memorandum of Association, specifically Clause 3 (Objectives), in order to encompass the current and future business operations of the Company.

On May 1, 2023, the Company registered the reduction from the registered capital of 216,218,625.50 Baht to 196,798,646 Baht by canceling 38,839,959 shares of unpaid-up ordinary shares with the Department of Business Development

On May 2, 2023, the company registered an increase in its registered capital from 196,798,646 baht to 243,363,711.50 baht by issuing 93,130,131 additional ordinary shares to accommodate the exercise of warrants (No. 2) with the Department of Business Development.

On May 15, 2023, the change of Chief Accountant from Ms. Nattaya Nounklay to Ms. Supaporn Chanwongngam

On June 21, 2023, the Company issued an offering of warrants to purchase ordinary shares of Company No. 2 ("IP-W2") to existing shareholders in proportion to their shareholding, 93,129,691 units.

On June 23, 2023, Mrs. Nattarin Polpuech resigned as Director and Chief Financial Officer due to her other business engagement, and the Company has appointed Mrs. Chatkaew Krudkosol, Acting Chief Financial Officer.

On September 30, 2023, the warrants to purchase ordinary shares of Company No. 1 ("IP-W1") will delist.

2,024

On April 26, 2024, the 2024 Annual General Meeting of Shareholders resolved to approve important matters as follows:

  • Approved the dividend payment in form of ordinary shares of the Company from the retained earnings of not exceeding 232,825,328 shares at par value of Baht 0.50 per share to the shareholders at the ratio of 8 existing share to 5 stock dividend, totaling of not exceeding baht 116,412,664 or equivalent to the dividend payment at the rate of baht 0.3125 per share and the dividend payment in cash to shareholders at the rate of baht 0.0348 per share, totalling not exceeding baht 12,963,714.2352 (to accommodate for 10 percent withholding tax of assessable income pirsuant to Section 50 (2) (Jor) of the Thai Revenue Code for the dividend’s receiver). Including the dividend payment is at the rate of Baht 0.3473 per share, totaling not exceeding Baht 129,376,378.2352. The date to determine the list of shareholders entitled to receive the dividend is May 8, 2024 (Record Date), with dividend payments scheduled on May 24, 2024.

  • Approved the allocation of net profit for 2023 as legal reserve in the amount of 2.91 million baht.

  • Approved the capital decrease of 10,538,604 baht from 243,363,711.50 Baht to 232,825,107.50 baht by canceling 21,077,208 shares of unpaid-up ordinary shares.

On May 14, 2024, a reduction in registered capital from 243,363,711.50 baht to 232,825,107.50 baht by canceling 21,077,208 shares of unpaid ordinary shares with the Department of Business Development.

On May 15, 2024, registered an increase in registered capital from 243,363,711.50 baht to 378,387,365 baht by issuing 291,124,515 additional common shares to support the dividend payment in common shares and to support the adjustment of the exercise rate of the second warrant (IP-W2) with the Department of Business Development.

On May 24, 2024, registered capital increased from 186,260,262 baht to 302,672,149.50 with the Department of Business Development

On August 1, 2024, IP securities were moved to be traded on the Stock Exchange (SET).

On September 3, 2024, the Board of Directors' Meeting No. 4/2024 passed a resolution approving the company to enter into investment by purchasing shares in Metta Medtech Company Limited (“Metta”) which operates the business of selling medical equipment and medical equipment Including rental and maintenance of such tools and equipment and provides rehabilitation medicine and physical therapy services in the proportion of 60 percent of the issued and paid-up capital of Metta.

2,025

On 1 April 2025, the Company signed a cooperation agreement with Zhaoke Ophthalmology Company Limited (“Zhaoke”), a company listed on the Hong Kong Stock Exchange and a subsidiary of Lee’s Pharmaceutical Holdings Limited. Zhaoke is a leading company in comprehensive eye care innovation, offering products such as eye drops for myopia, hyperopia, dry eye, and glaucoma. This collaboration establishes the Company as the exclusive distributor for Zhaoke’s comprehensive eye care innovations in Thailand. Furthermore, the partnership extends to utilizing the Company’s manufacturing facility as a production base for ophthalmic drugs in Southeast Asia to meet global market demands.

On June 21, 2025, the warrants to purchase ordinary shares of Company No. 2 ("IP-W2") delisting date.

On 20 August 2025, the Company applied to participate in the “Jump Plus (JUMP+)” Program, organized by the Stock Exchange of Thailand, with the objective of driving growth and creating sustainable long-term value for the Company.

On 11 November 2025, the Board of Directors’ meeting resolved to approve the Company to purchase ordinary shares of Interpharma- ZEAvita Company Limited (“IP-Z”), which is an associate company of the Company, with a total of 980,000 shares, thereby making Interpharma-ZEAvitta Company Limited a subsidiary of the Company.

On 21 November 2025, Interpharma-ZEAvitta Company Limited registered a change of its company name to Global Advance Marketing Company Limited with the Department of Business Development, Ministry of Commerce.

Use of Proceeds from Securities Offerings

Is There Money Raised from a Securities Offering Still to Report On?

No

Commitments Made in the Registration Statement

Are There Commitments or Conditions from an Offering or Listing?

No

Group Operating-Structure Policy

Description

The Company has an investment policy to invest in businesses related to its core business that have profit-generating potential, growth opportunities, or create synergies to enhance the Company’s profitability. In making such investments, the Company takes into account the expected returns and exercises control and supervision over the management of its subsidiaries in a manner equivalent to internal business units. The Company continuously monitors their operations to safeguard its investment interests on an ongoing and sustainable basis, while creating long-term value and maintaining confidence among stakeholders. The Company has established policies for the control and supervision of subsidiaries and associated companies in which it has invested. Appropriate management and governance structures have been defined to ensure effective oversight, management accountability, and responsibility for the operations of such subsidiaries and associated companies. In this regard, the Company nominates directors and executives of subsidiaries and associated companies in proportion to its shareholding or in accordance with relevant agreements. For investments in associated companies, the Company does not have a policy to exercise significant control. The appointment of the Company’s representatives to serve as directors of associated companies shall be determined based on appropriateness and mutual agreements. Such representatives must possess appropriate qualifications and experience relevant to the management of the respective subsidiaries and associated companies.

Companies Where the Company Holds ≥10%

Companies (≥10% Holding)

Company NameAddressProvinceZip CodeTelephoneBusiness TypeSecurity TypeSharesPaid-up Shares
Inter Vetta Company Limited140/9 ITF Tower 9 Floor, Silom Road, Suriyawong, Bangrak.Bangkok1050002-634-0225Import and distribute healthcare products for pets and livestock.Common shares50,00050,000
Inter Petrina Company Limited140/9 ITF Tower 9 Floor, Silom Road, Suriyawong, BangrakBangkok1050002-634-0225Operate a business related to pet food products. It is the owner of the “MARIA” brand and has released MARIA dog and cat food products which are wet food made from various raw materials that are real meat, such as chicken, tuna, salmon, rice fish, katsuobushi, liver, etc., which is the same grade of raw material that produces human food. The production is subcontracted by an affiliated factory of Asian Group Service Co., Ltd., which is another joint venture that specializes in producing premium pet food with an innovative production quality standard that has been accepted by the world's leading markets and is a manufacturing subcontractor (OEM) for leading brands in the pet food group.Common shares40,00040,000
Global Advance Marketing Company Limited140/9 ITF Tower 9 Floor, Silom Road, Suriyawong, BangrakBangkok1050002-634-0225To provide advertising, public relations, marketing communications, and sales promotion services through all types of media.Common shares2,000,0002,000,000
Inter Pharmacy Company Limited140/9 ITF Tower 9 Floor, Silom Road, Suriyawong, BangrakBangkok1050002-634-0225Holding CompanyCommon shares3,989,8243,989,824
Inter Wellness Company Limited160/74 ITF Silom Palace 10 Floor, Silom Road, Suriyawong, Bangrak,Bangkok1050002-634-0225Holding CompanyCommon shares4,300,0004,300,000
Drug Care Company Limited191 Silom Complex Building, Unit 1, 21 Floor, Silom Road, Silom, Bangrak1050002-231-3116PharmacyCommon shares1,123,6501,123,650
Interpharma medtech Company Limited18/110 -111 Lat Krabang Road, Lat Krabang Subdistrict, Lat Krabang DistrictBangkok1052002-123-3025Selling medical equipment and medical equipment Including rental and maintenance of such tools and equipment. and provide rehabilitation medicine servicesCommon shares100,000100,000
Modern Pharma Company Limited197/1 Moo 1, Suksawat Road, Tambon Pak Khlong Bang Pla Kot Phra Samut Chedi DistrictSamut Prakarn1029002-425-1126Manufacture and distribute healthcare products for humans and animalsCommon shares2,950,0002,950,000
Nakhonpat Inter Company Limited2/99 Pattanakarn Khu Khwang Road, Nai Mueang Subdistrict, Mueang Nakhon Si Thammarat District Nakhon Si Thammarat80000075 305 999HospitalCommon shares5,000,0005,000,000
NKP Management Company Limited2/99 Pattanakarn Khu Khwang Road, Nai Mueang Subdistrict, Mueang Nakhon Si Thammarat District Nakhon Si Thammarat80000075 305 999Food Preparation and Patient Laundry Services”Common shares10,00010,000

Shareholders with Potential Conflict of Interest

Has Potential-Conflict Shareholder (Y/N)

No

Relationships Among Major Shareholders

Relationship Exists (Y/N)

No

Shareholders' Agreement

Agreement Exists (Y/N)

No

Shareholding Diagram (Group Structure)

Does the company hold shares in other companies?

Yes

Subsidiaries

Company NameJuristic Persons / Holders
Inter Vetta Company LimitedINTER PHARMA PUBLIC COMPANY LIMITED · Voting rights percent: 55.0 · Shareholding proportion percent: 55.0 · M-Natur Plus Company Limted · Voting rights percent: 40.0 · Shareholding proportion percent: 40.0
Inter Petrina Company LimitedINTER PHARMA PUBLIC COMPANY LIMITED · Voting rights percent: 60.0 · Shareholding proportion percent: 60.0 · Asian Alliance International Public Company Limited · Voting rights percent: 40.0 · Shareholding proportion percent: 40.0
Global Advance Marketing Company LimitedINTER PHARMA PUBLIC COMPANY LIMITED · Voting rights percent: 100.0 · Shareholding proportion percent: 100.0
Inter Pharmacy Company LimitedINTER PHARMA PUBLIC COMPANY LIMITED · Voting rights percent: 100.0 · Shareholding proportion percent: 100.0
Inter Wellness Company LimitedINTER PHARMA PUBLIC COMPANY LIMITED · Voting rights percent: 100.0 · Shareholding proportion percent: 100.0
Drug Care Company LimitedINTER PHARMA PUBLIC COMPANY LIMITED · Voting rights percent: 0.0 · Shareholding proportion percent: 0.0 · Inter Pharmacy Company Limited · Voting rights percent: 88.67 · Shareholding proportion percent: 88.67
Nakhonpat Inter Company LimitedINTER PHARMA PUBLIC COMPANY LIMITED · Voting rights percent: 0.0 · Shareholding proportion percent: 0.0 · Inter Wellness Company Limited · Voting rights percent: 50.0 · Shareholding proportion percent: 50.0
Interpharma medtech Company LimitedINTER PHARMA PUBLIC COMPANY LIMITED · Voting rights percent: 60.0 · Shareholding proportion percent: 60.0
Modern Pharma Company LimitedINTER PHARMA PUBLIC COMPANY LIMITED · Voting rights percent: 100.0 · Shareholding proportion percent: 100.0
NKP Management Company LimitedINTER PHARMA PUBLIC COMPANY LIMITED · Voting rights percent: 0.0 · Shareholding proportion percent: 0.0 · Nakhon Patana Inter Company Limited · Voting rights percent: 100.0 · Shareholding proportion percent: 100.0

Income Structure

Product / Service Income

CategoryDescriptionThis YearThis Year %Last YearLast Year %2 Years Ago2 Years Ago %
Total revenue from operationsTotal revenue from operations2,214,0601001,911,9471001,798,775100
Human Healthcare1,820,00882.21,550,95181.121,429,17979.45
Animal Healthcare373,48116.87346,37818.12352,05519.57
Other income20,5710.9314,6180.7617,5410.98
OtherOther000000

Export Income

CategoryDescriptionThis YearThis Year %Last YearLast Year %2 Years Ago2 Years Ago %
Total revenueTotal revenue from operations2,214,0601001,911,9471001,798,775100
DomesticDomestic2,214,0601001,911,9471001,798,775100
InternationalInternational000000
OtherOther000000
Other countriesOther countries000000

Other Income

Operating Other IncomeNon-Operating Other IncomeShare of Profit
1710 · As of year: 0.0 · Description: Total other income · As of yesteryear: 0.0 · As of year before yesteryear: 0.0 · 1711 · As of year: 0.0 · Description: Other income from operations · As of yesteryear: 0.0 · As of year before yesteryear: 0.01712 · As of year: 0.0 · Description: Other income not from operations · As of yesteryear: 0.0 · As of year before yesteryear: 0.01713 · As of year: -1233.0 · Description: Share of profit · As of yesteryear: -1589.0 · As of year before yesteryear: -2274.0

Product / Service Characteristics

Business Type

3114

Business Groups

Business GroupDescription
Pharmaceutical Products

The pharmaceutical product group that focuses on drugs for treating diseases related to the gastrointestinal system, respiratory system, diabetes, muscle and bone structure, painkillers, and infection-fighting general medicines. The Company focuses on its products to make the most of the patient's treatment and, at the same time, meet the growing demand from both physicians and health insurers. This product group includes various products under the Company's brand: Zensil, Bella Para, Zimmex, Virogon, Aller-Tab, Ingesic, Merforin, P-Fen, Omezole, Supenac, Bubble-X, Itrazole, Zyritine, and Pyrana. The Company has its own 2 pharmaceutical factories in Thailand, Phra Nakhon Si Ayutthaya Province and Samut Prakan Province.

Pharmaceutical Products

Wellness and Anti-Aging Products
  1. Wellness and Anti-Aging Products

The products that help maintain healthy and anti-aging health and are not drugs that focus on balancing internal organs. They are called "Nutraceuticals". The products are developed from nutrients that have been proven effective in treating disease prevention and promoting health without side effects. This product group includes various products under the Company's brand: Probac 7, Probac 10 Plus, Probac BL, Beta Glucan Plus, Pure Krill Oil, PreBO, Astacurmin, ProLivo, Bravo Fit, Wonder Fit, Probac Fit, Fibo Fit, Protein Fit x2, Probac Ultra Collagen, Multivitamin, Magnesium plus B complex, Probac Mood, D choless, and Prohare, as well as the products that the Company is a distributor for other product owners, including TS6 - Synbiotic.

  1. Aesthetic Innovation Products

Innovative products about various aspects of beauty that help increase the dimension and clarity of the face, and cleansing. This product group includes the products that the Company is a distributor for other product owners under the Company's brand: TS6 - Lady Health, and the products under the Company's brand, namely YUUU toothpaste.

Animal Healthcare

Companion Animal Health Products are operated through the Company’s subsidiary, Inter Vetta Co., Ltd., comprising the following products:

  1. Nutraceuticals for pets are food supplements for the health care of dogs and cats. Each product contains various nutrients that helps nourish and reduce the symptoms of various diseases, such as calcium deficiency, helping reduce inflammation, itching, and hair loss, maintaining the health of the skin and coat to be soft and beautiful, and nourishing the nervous system and metabolic system, helping reduce arthritis problems and osteoarthritis, slowing down the symptoms of cancer, etc. This product group consists of the products that the subsidiary is a distributor for other product owners, such as Dr. Choice Pet Selectand SYNBIO-B, and the products owned by the subsidiary itself, such as Katimun Qcer, SAMe, QrillMega, and cluvita Soft Chew.

  2. Medicated Shampoo for pets is a shampoo to treat skin infections in dogs and cats. This product group includes the products that the Company is a distributor for other owners, namely Dermcare MALASEB and Dermcare PYOHEX.

  3. Cosmeceuticals for pets are a type of shampoo and conditioner that do not need to be rinsed for dogs and cats with dry, itchy, or sensitive skin. They keep skin and coat soft and beautiful, reduce tangles, and prevent skin irritation, including products for cleaning the ear canals of pets and multi-purpose spray for pets. This product group consists of the products that the Company is a distributor for other owners, such as Dermcare Aloveen and Dermcare Natural, and the products that are owned by the subsidiary itself, such as EARkleen, EARkleen PLUS, Dentakare GEL, Qbac and Qcer Gel.

  4. Pharmaceuticals for pets include drugs for dogs and cats such as antibiotics, pain relievers, anti-inflammatory drugs, ear drops, anthelmintics, etc.This product group consists of the products that the subsidiary is a distributor for other product owners, namely MOXCLAVET, ENROPHAR, MARBOFLOX, FENAMAX TABLET, OTOPET OINTMENT, and PRABENGUARD.

  5. Vaccines for pets include vaccines for dogs and cats. They are the combined vaccine to protect against major infectious viral diseases in dogs and cats, including rabies. This product group consists of the products that the subsidiary is a distributor for other product owners, namelyBiocan NOVEL DHPPi/L4R, CANGLOB P, CANGLOB D, FORTEand FELIMUN

  6. Pheromone Products for Pets are synthetic pheromone-based products designed to help reduce stress, anxiety, and undesirable behaviors caused by stress or environmental changes. Such behaviors may include urinating outside the litter box, scratching furniture, aggression, hiding, or stress related to travel, relocation, veterinary visits, or cohabitation with other pets.

    This product category includes items for which the Company’s subsidiary serves as a distributor on behalf of brand owners, namely FELIWAY Spray, FELIWAY Diffuser, and FELIWAY Refill.

  7. Pet food is a food product for dogs and cats. This product group consists of the products under the subsidiary’s brand namely, MARIA, which is a premium-quality human-grade food product under the concept of "Authentic Pet Food," which is made from real chicken and fish meat, not meat scraps or processed meat, or By Product. There are also products for which the subsidiary is a distributor for other product owners, namely Choo Choo, which consists of Choo Choo concentrated soup for health care consisting of 20 natural protein amino peptides, Choo Choo jelly supplementary food for cats, Choo Choo smoothie for cat health, Choo Choo baby cat soup for kitten health and Choo Choo Super Protein Booster

  8. Pet Pee Pad is a product for absorbing urine or excretion for dogs, cats, and general pets under the brand Raku Pad, which is a subsidiary’s brand.

Pharmacy Business

Inter Pharmacy Co., Ltd., a subsidiary of the Company, invested by acquiring a 88.67 percent equity interest in Drug Care Co., Ltd. (“Drug Care”). Drug Care operates a retail business in pharmaceutical products, cosmeceuticals, and medical supplies for domestic customers, offering a selection of more than 7,000 pharmaceutical, medical, and health-related products. The business operates under the trademark LAB Pharmacy, with sales and service channels through physical pharmacy branches and online platforms (Shopee and Lazada). At present, Drug Care operates a total of 50 branches.

Hospital Business

Inter Wellness Co., Ltd., a subsidiary of the Company, has invested by acquiring shares of Nakhonpat Inter Co., Ltd. (“Nakhonpat Inter”) (Original name “Nakhon Patana Co., Ltd.”) in the proportion of 50%. Nakhonpat Interoperates a private hospital business and nursing home. Its status is of a medium-sized general hospital with 59 beds, namely, Nakhonpat Inter Hospital. The license to operate the business number is 10201001661, dated April 30, 2018, and the license to operate as a medical facility number is 10201001851, dated April 30, 2018, which is the current version. Nakhonpat Inter Hospital is located on land title deeds No. 62887 and 62889, Nai Mueang Sub-District, Mueang Nakhon Si Thammarat District, Nakhon Si Thammarat Province. The areas have 6 rai 84.6 square wa and 1 rai 3 square wa. Dr. Pornchai Leelanonpon operates the hospital, which consists of in-patients, out-patients (OPD), ICU, obstetrics and gynecology, surgical, cardiology medicine, cardiothoracic, kidney, MRI, X-RAY, dental, physiotherapy, rehabilitation, and emergency departments.

Medical equipment distribution business

The Company invested by acquiring a 60% equity interest in Interpharma Medtech Co., Ltd. (“IPM”) (formerly known as Metta Medtech Co., Ltd.). IPM engages in the distribution of medical devices under the medical device importation license (No. SorNor. 39/2560) dated 15 February 2017, and operates two physical therapy clinics, namely InterRehab NeuroBridge Sammakorn Place Ramkhamhaeng, under the healthcare facility operating license No. 10110002365 dated 2 July 2024, and InterRehab Brain&Pain Total Office Syndrome Solution, under the healthcare facility operating license No. 10110002365 dated 14 January 2025.

Research & Development

Has R&D Policy (Y/N)

Yes

R&D Cost — Description

The Company focuses on building a strong brand with continuous research and development in products to be improved to achieve the goals of being a leading Company in providing health products with an emphasis on excellent products so that consumers have good health. In the past, the Company has been successful in researching and developing products with outstanding features, variety, and differentiation from other products in the market, such as an introduction of biotechnology by using probiotics and prebiotics as an ingredient invented to create a balance in the body's system, prevent disease, and help the body to be stronger. This meets the needs of consumers who care about their health, anti-aging, and have a longer life. In addition, the Company has cooperated with partners who are contracted manufacturers both domestically and internationally in developing production formulas and technology to get products that are effective with more benefits to build credibility and acceptance in the market. It also creates a reputation and strength for the brand "INTERPHARMA" by having high-quality products comparable to other leading brands' products. The Company believes that good and continuous product research and development will provide the Company with a competitive advantage over competitors in the same industry in the long run.

In addition, the Company has also conducted research with the company's partners. which are as follows:

1. Joint research with Asian Seafoods Coldstorage Public Company Limited for the development of dog and cat food under the brand “MARIA” by inventing dog and cat food recipes, which are the Company's recipes. and exported to foreign countries.

2. Research work with Thai Union Group Public Company Limited to develop products made from fish bone. Fish oils under the “ZEAVITA by Interpharma” brand, namely ZEAVITA LISA DHA SHOT, TUNA BONE and FISH PRO, are formulated by the Company. which the company plans to export to sell in foreign markets and is an operation from upstream to downstream.

  • In 2021, the company signed a Memorandum of Understanding (MOU) with Prince of Songkla University (PSU) to research and develop kratom and extract it jointly. It is a comprehensive health product of international standards, such as pharmaceuticals, nutritional therapy, food supplements, health drinks, etc. The joint project is partly funded by research and innovation from Program Management Unit Competitiveness (PMUC). This is another essential step in becoming a leading company in research, development and offering world-class comprehensive health products. At present, the construction of the factory has been completed.

  • In 2022, the Company has researched and developed ophthalmic products. to produce eye drops and cataract drugs according to EU standards at the Company's factory in Ayutthaya which the Company expects to complete within the year 2026.

  • In 2024, the Company entered into a collaboration agreement with Onodera Group, Japan, to jointly conduct research and development on the treatment of Parkinson’s disease using gene therapy. The Company has researched and developed probiotics in the form of Vegan Capsule, which is an innovative Time Release Capsule that can withstand stomach acid and gradually break down well, protects probiotics from being destroyed by stomach acid, allowing them to work effectively in the intestinal tract.

  • In 2025, the Company entered into a collaboration agreement with Zhaoke Ophthalmology Limited to strengthen its ophthalmic therapeutic portfolio, covering key products such as eye drops for myopia and hyperopia, anti-glaucoma medications, as well as innovative therapies.

  • The company has developed an innovative product incorporating CBP, a concentrated protein extracted from cow’s milk, in an amount equivalent to consuming 53 liters of milk. It is conveniently packaged in a single sachet to help promote the function of bone-forming cells and strengthen bone health, making it suitable for individuals with osteoporosis. In addition, it supports height growth in children during their developmental years and helps enhance the immune system. The product is tasty, easy to consume, and provides comprehensive health benefits.

    Prebo Gummy

  • Dr. YUUU Anti Acne Gel, the company has conducted research and development on an anti-inflammatory acne spot gel, which has been clinically tested by dermatologists from the Dermaproof Asia Institute. The test results show that the product can help reduce inflammatory acne within 1 day after use. The formulation incorporates Salsphere technology, an innovation that encapsulates active ingredients to enhance their stability and effectiveness in reducing acne formation. It is also enriched with natural extracts that help control excess facial oil and gently reduce acne inflammation. The company plans to launch the product in March 2026 and expects it to generate significant revenue, as it effectively meets the needs of the teenage consumer market.

    Anti Acne Gel

  • Modern Pharma (OEM manufacturer) has developed an innovative coating technology for calcium tablets by adding a sweet taste and blueberry flavor. This enhancement helps make the product easier to consume, especially for pregnant women. It also helps reduce the unpleasant odor of calcium, resulting in a better taste and improved palatability. This innovation has been developed to meet the needs of OEM customers.

R&D Cost — Label

Research and development (R&D) expenses over the past 3 years (Million Baht)

R&D Cost — This Year

2538667.0

R&D Cost — Last Year

487173.21

R&D Cost — 2 Years Ago

1571833.0

Assets Used in the Business

Permanent Assets — Description

The Company and its subsidiaries possess assets in the categories of lands, buildings, and equipment. The net book value on December 31, 2025, is 1,096.92 million Baht.

Permanent Assets — Appraisal

AssetOwnershipObligationAppraisal Value
Landownercollateral against credit facilities received from financial institutions333.9
Buildings and land and buildings improvementsownercollateral against credit facilities received from financial institutions432.24
Condominium unitowner-4.91
Machinery and equipmentownercollateral against credit facilities received from financial institutions100.72
Tools and office equipmentowner-40.14
Furniture and fixturesowner-4.29
Vehiclesowner-17.71
Water systemowner-0.59
Assets under installationowner-162.42

Intangible Assets — Description

As of December 31, 2025, the Company and its subsidiaries were the copyrights owners of music, computer programs, trademark, customer relationships, drug registrations pending transfer, and trade names with a net book value of 219.82 million Baht. A policy to amortize on a straight – line method over a lifetime of these assets is 3-30.75 years.

Intangible Assets — Appraisal

AssetTypeType (if Other)Appraisal Value
Computer softwareSoftware23.44
CopyrightCopyright0.36
TrademarkTrademark0.24
Drug registrationOthersDrug registration30.84
Brand nameOthersBrand name89.31
Customer relationshipsOthersCustomer relationships16.23
Assets in progressOthersAssets in progress59.4

Has Subsidiaries Investment Policy (Y/N)

Yes

Subsidiaries Investment Policy — Description

The Company has an investment policy to invest in businesses that are aligned with its objectives, vision, and strategic plans, including businesses related to its core operations that have profit-generating potential, growth opportunities, or create synergies to enhance the Company’s profitability. In making such investments, the Company considers the expected returns and exercises control and supervision over the management of its subsidiaries and associated companies through appropriate governance structures, treating them as integral parts of the Company. The Company continuously monitors their operations to safeguard its investment interests on a sustainable basis, while creating long-term value and strengthening confidence among stakeholders.

Marketing Policy & Competition

Reporting Mode

3117

Marketing Policy (Overall)

Marketing Policy

The Company has established a marketing and advertising policy based on ethical principles and social responsibility, as outlined below:

1. Honesty and Truthfulness

The Company shall present marketing and advertising content that is accurate and truthful in order to build customer confidence in its products and services. All marketing communications shall be conducted in compliance with applicable laws and regulations, with due regard to consumer rights.

2. Avoidance of Exaggerated Claims

The Company shall not use statements or visual representations that lack factual support, are ambiguous, misleading, distorted, exaggerated, or likely to cause misunderstanding in any aspect of marketing and advertising. The Company shall also refrain from supporting advertisements or promotional activities that encourage unlawful or unethical conduct.

3. Protection of Vulnerable Groups

The Company is committed to protecting vulnerable market groups, such as children and youth, as well as individuals with limited educational opportunities, and shall not seek to exploit such groups through marketing activities.

4. Respect for Stakeholders

The Company respects all stakeholders and shall ensure that marketing communications are appropriate and responsible. The Company shall avoid damaging the reputation of competitors or other stakeholders through false or exaggerated information.

5. Respect for Consumer Rights

The Company respects consumers’ decision-making rights and encourages customers to exercise their rights. Appropriate measures shall be implemented, such as informing customers of their rights regarding personal data protection and providing comprehensive information on the environmental, health, and safety impacts of products and services. This is to support informed decision-making based on accurate, complete, and sufficient information.

6. Proper and Secure Collection and Use of Data

The Company shall collect consumers’ personal data based on strict consent principles and in accordance with applicable laws, including the Personal Data Protection Act (PDPA). Personal data shall be used appropriately for the purpose of enhancing consumer experience and improving service quality within the legal framework.

7. Personnel Training and Digital Skills Development

The Company promotes knowledge and understanding among marketing and advertising personnel regarding the technologies utilized, as well as the ethical use of digital technologies. This ensures that technology is applied effectively within the boundaries of the law and with due responsibility toward society and consumers.

8. Continuous Improvement and Customer Relationship Development

The Company is committed to addressing and improving its operations in response to customer feedback in order to continuously enhance and strengthen long-term customer relationships.

Competitive strategy

1) Offering High Quality Products

The Company believes that the quality of products will affect the success and sustainability of business growth and helps in customer satisfaction and repeat purchase rates. Includes developing products and offering new quality products and innovations to the market continuously. The Company places importance on the invention, development, and presentation of good quality and high-efficiency products to meet consumer standards and safety. These are to build credibility, provide differences from the same type of products in the market, and meet the needs of consumers entirely.

The Company has the policy to select and employ both domestic and foreign manufacturers with standardized production and can produce and procure high-quality and efficient raw materials to meet the components that the Company and its unique formula require. All products must be tested before being marketed to ensure that the products are good, quality, and reliable, strengthening the Company's product brand and the potential to compete in the long run. Regarding supplying other products from the outside for sales, the Company has a selection process of reliable products under standardized production and has a license to compete in the markets.

For products manufactured at the Company’s facilities, the Company places strong emphasis on quality control at every stage of the production process, ranging from the selection and inspection of raw materials, production process control, and in-process testing, to the quality inspection of finished products prior to distribution. Operations are conducted under standardized systems and practices that are in compliance with Good Manufacturing Practice (GMP) and/or other relevant standards, in order to ensure that products consistently meet the Company’s requirements for quality, efficacy, and safety.

Having its own manufacturing facilities enables the Company to closely supervise product quality, enhance flexibility in formulation development, and continuously improve production processes in alignment with academic standards, market demand, and applicable regulatory requirements. These factors are key to strengthening product credibility and reinforcing the long-term resilience and strength of the Company’s brand.

In addition, the Company continuously monitors and analyzes market situations for product development and new product acquisition to suit the market's competitive conditions, popular trends, and changing needs, as well as to get more benefits from the products.

2) Promoting Products and Brands to be Widely Known

The Company focuses on marketing to create knowledge and understanding about the features and strengths of the products for consumers. It creates awareness, trust, and recognition of the Company's brand, affecting consumers' buying decisions. The Company believes that marketing encourages consumers to be more interested in health, which will positively affect the Company's products. The Company's health-related products contain nutrients and minerals with various properties. It is generally accepted through scientific literature about the properties and efficiency of the components of a particular product. The Company regularly presents product knowledge to create interest among consumers through marketing, advertising, providing academic information, and disseminating knowledge, understanding, and benefits of each product in easy-to-understand formats through media such as magazines, leaflets, brochures, television programs, websites, etc., including providing product samples to encourage product trials. It needs a product that will assist the Company in gaining more revenues and market shares.

The Company has promoted products and sales through many online channels. This makes communicating with customers convenient and fast. The Company has provided online media such as Facebook: Interpharma Thailand, Instagram: interpharmaofficial, Line@ ID: @interpharma, Tiktok Interpharma Thailand etc. An online shopping channel is provided at www.interpharmastore.com. The Company set up a Call Center via telephone number 0-2634-0225 or 08-2422-5999 to facilitate customers to contact the Company directly. Customers can ask for product details, express their opinions, recommend, criticize, or report problems with products or services. Therefore, the needs and problems of each customer are acknowledged for further improvement as well as for creating a good relationship between the Company and customers in the long run.

3) Expanding Distribution Channels to Overseas Markets

The Company aims to be a leader in offering health products. The Company will expand distribution and marketing channels domestically and internationally so that target customers can easily access the products. Currently, the Company and its subsidiaries sell products only in the country through distribution channels, including hospitals, shops, pharmacies, modern trade, traditional trade and online channels. According to the plan, the Company aims to expand distribution channels for its branded products to new markets in foreign countries as an opportunity to increase sales by planning to market and sell all of the Company's products in Southeast Asia, including CLMV countries and other Asian countries such as South Korea and China, etc., as well as seeking business partners to open markets in Europe and America.

The Company is currently at an early stage of international marketing and has begun to establish a systematic business foundation, particularly in terms of personnel, knowledge, understanding of product registration procedures, and compliance with regulatory requirements applicable to business operations in each country. The Company focuses on building strong relationships with overseas partners and business networks through participation in seminars, conferences, exhibitions, and trade fairs, as well as through collaboration with government agencies and organizations responsible for the promotion of international trade, such as the Department of International Trade Promotion, as channels for market exploration and the creation of opportunities to enter new markets.

At present, the Company has commenced the export of pharmaceutical products to neighboring countries and nearby economic territories, namely the Republic of the Union of Myanmar, the Lao People’s Democratic Republic, and the Hong Kong Special Administrative Region. This represents an initial step in expanding the Company’s international customer base and serves to accumulate experience in operations, product registration, and regulatory management, in preparation for future market expansion into other countries within the region.

4) Adding More Variety of Products

The Company places importance on developing, inventing, and presenting new products with more variety to meet the needs of each group of customers individually. The Company will benefit from existing customers who already prefer those products. This results in increased interest in purchasing new products. It can also increase a new customer base for new products. Each year, the Company has launched new products with different properties that can cover more health and beauty care.

In 2021, the Company launched 6 new products including Probac FIT 2 sku, synbiotics for weight control, Bravo FIT 10 capsules for men's holistic health, Wonder FIT 30 capsules for women's holistic health to reduce menstrual pain and menopausal symptoms; TS6 10 sachets (For skin), synbiotics for skin, Probac Ultra Collagen 30 sachets, collagen mixed with synbiotics for skin and reducing wrinkles, and Protein Fit x2 10 sachets, a plant-based protein for weight control and building muscle mass.

In 2022, the Company launched 3 new products include Probac Mood, synbiotics to help reduce stress, Magnesium, a magnesium effervescent tablet mixed with vitamin B complex to help reduce inflammation of the muscles and migraine symptoms, and D choless to reduce cholesterol and stimulate blood circulation

In 2023, the Company launched 1 new product, Prohare, reducing issues of hair loss and thin hair as well as creating new hair Bella, trinn.

In 2024, the company launched a new product, Probac Bio Active, a probiotic in the form of a Vegan Capsule.

In 2025, the Company launched two new products. The first is Magnesium Plus B Complex, an effervescent tablet formulation that dissolves quickly in water, is easy to consume, and allows for efficient absorption, making it suitable for individuals seeking daily magnesium supplementation. The second product is PreBO Gummy, a high-concentration protein gummy designed to support growth and height development in children, while also helping to prevent osteoporosis in adults.

Industry & Competition (Overall)

Industry Condition and Competition

Health and anti-aging products distributed by the Company are classified as dietary supplements, which are highly competitive. There are many entrepreneurs in this business, both factories that produce products and sell themselves and contracted factories that produce products for various entrepreneurs. Many entrepreneurs import products from abroad or a subsidiary of a foreign Company with a branch in Thailand. The direction of competition is in line with the behavior of consumers, who are more health-conscious and give importance to taking care of and enhancing the image of their body and face, as well as the direction of the population of Thailand, which is about to become a completely aging society in 2021 and the fact that consumers want to avoid side effects from drug treatment. These are essential factors for choosing more health products, especially the innovative health care and anti-aging products that provide nutritional value and have research evidence that certain nutrients are effective in preventing disease and promoting health without side effects, such as helping with memory, digestive system, absorption, blood circulation, sleep, eye care, bones, muscles, help excretion, etc. In addition, the competition of various entrepreneurs also comes from searching for products that consumers can easily gain from recognizing and quickly accessing relevant information through multiple channels, especially social media. Health products can be purchased more conveniently from many channels such as pharmacies and modern retailers, online channels, direct sales agents, etc., resulting in the increased presentation of various products for consumers' choice.

The pet health product demands are highly competitive. There are many entrepreneurs in this business. Nowadays, pets are considered a part that plays a role in the lifestyle with more people who are single, childless married couples, stepping into an aging society, people living longer, and having fewer children; these factors drive pets more like companions or replacements. The number of pets appeared to have increased in Thailand. This has a positive effect on pet-related businesses, so those businesses have grown accordingly.

Regarding an overview of the competition in health products for humans and animals, most entrepreneurs focus on product quality and formulation, brand image, and attitude towards a brand and their products. The other supporting factors related to consumer product purchasing are a manufacturer's reputation, price, marketing and promotion activities, innovation and production technology, packaging appearance, distribution channels, etc. If any product has high credibility and a good brand image, there is a distinctive difference from other competing products. If the products are diverse and meet consumers' needs, including having a channel that is easy and convenient, the product has a higher chance of being bought or used by consumers. Market competition in each product group that the Company and its subsidiaries sell can be divided into 4 groups as follows:

1. Pharmaceutical Products

The Company places importance on medicines for treatment. The Company focuses on product quality, which consumers value the most, and places importance on the production process and quality control. There is also a product analysis in every production line before selling out to our consumers, as we realize that the safety of consumers is essential. The Company's pharmaceutical factory meets internationally recognized standards (GMP-PIC/S). We are committed to developing and innovating our products to support the growth of the country's drug markets and the export market. The Company has experienced sales staff and teams proficient in sales through drug distribution at the hospital channel, over-the-counter (OTC), Traditional Trade, and clinics at a reasonable price. This makes medicines more accessible. When combined with the selling point of quality in drugs and a standard in delivery services with lower costs compared to an original product, the above factors will attract patients to have access to the Company's medicines and healthcare services, contributing to increased demand.

2. Anti-Aging Product Group

The synbiotic product group, including Probac 7 and Probac 10 Plus, comprises health products for which the Company is a pioneer and which are differentiated from general dietary supplements available in the market. The number of direct competitors in the market is limited, and they are primarily companies that import pharmaceutical and healthcare products from abroad, such as Abbott Laboratories (Biogaia dietary supplement). However, such companies differ significantly from the Company in terms of business scale, both in revenue and assets; therefore, competitiveness cannot be compared solely on the basis of business size. Although there are currently a large number of manufacturers and distributors of synbiotic products in the market, most products are still unable to compete with the Company’s synbiotics in terms of quality and functional efficacy, particularly in the area of targeted health care and health promotion. The synbiotic products of Inter Pharma Public Company Limited are developed with formulations that emphasize specificity toward particular health conditions and disease management to a greater extent. As a result, competition within this product segment is driven primarily by product quality, supporting evidence, and the communication of tangible benefits that are clearly perceived by consumers, thereby fostering repeat purchases and long-term brand loyalty.

For other groups of dietary supplements the Company sells, for example, immune system boosting, Omega 3, combined nutrients for vital organs, antioxidant-rich, and multivitamin products, the competitors are manufacturers or distributors of dietary supplements both domestically and internationally which have general food supplements, such as Mega Lifesciences Public Company Limited (dietary supplements under the MEGA We Care brand), NBD Healthcare Co., Ltd. (dietary supplements under the Vistra brand), Blackmores Co., Ltd. (dietary supplements under the Blackmores brand), etc., The aforementioned competitors have different business sizes, revenues, and assets from the Company, making it impossible to compare them solely by considering the business size and which Company is a major competitor at the same level as the Company.

3. Beauty Innovation Product

The Company's main beauty innovation product group products are YUUU Advance Probiotic & Pine Needle Toothpaste. The critical competitors include Siam Health Co., Ltd. (Dentiste toothpaste)

4. Animal Healthcare Product Group

Healthcare products for pets other than pet food: Major competitors are as follows:

1) Pet nutrition product business: Most competitors in this category are manufacturers and distributors of pet food supplement products in Thailand, such as O Square Distribution Co., Ltd. (Mega O.F.A. Plus), Unovate Network Co., Ltd. (Ferric Plus-K, Caredio-Balance, etc.), T.J. Animal Health Co., Ltd. (AKTIVAIT, COATEX, SAMYLIN, SYNOQUIN, etc).

2) Dermatology shampoo, skin, cosmeceutical, and pet medicines business: Competitors in this category are the companies that import products for sales and companies that manufacture and distribute their own products, namely AnitechTotal Solution Co., Ltd. (Hartz shampoo), Virbac (Thailand) Co., Ltd. (Allermyl shampoo), T.J. Animal Health Co., Ltd. (Vet Novel shampoo), Bessie Aaron Co., Ltd. (Products Canine Care shampoo), and Veterina (Thailand) Co., Ltd. (Dermasebb shampoo), etc.

However, competitors with business size (measured by revenue size) and product lines similar to our subsidiaries (Inter Vetta) are, for example, Unovate Network Co., Ltd., T.J. Animal Health Co., Ltd., and Bessie Aaron Co., Ltd., etc.

3) Pet food products: Direct competitors in this pet food product category are manufacturers and distributors of processed pet food in Thailand which are made products from high quality chicken and fish raw materials as same as used in food production for human such as Pet Protect Food Co., Ltd. (Kanival, dog and cat food) Food Innova Trading and Service Co., Ltd. (Nekko, cat food), Hi-Q Food Products Co., Ltd. (Felina Canino pet food), etc. For indirect competitors, most are multinationals that are leading in pet food manufacturers and have a branch in Thailand, such as Royal Canin (Thailand) Co., Ltd. (Royal Canin, pet food), Hill's Pet Nutrition (Thailand) Co., Ltd. (Hill's Science Diet), etc. The rest are importers of pet food manufacturers and accessories for pets, such as Yiam Panich Pet Food Co., Ltd. (Orijen pet food), etc. However, since the subsidiary (Inter Petrina) has just begun operating and selling its products in 2018, the scale of Inter Petrina's pet food segment is not comparable to other competitors in the industry, both in terms of income and asset size.

Characteristics of Customers and Target Groups

Most of customers who order products of the Company and its subsidiaries are entrepreneurs such as hospitals, pet shops, livestock farms, traditional independent pharmacies, modern pharmacies, and modern retails (modern trade), etc. They purchase the products of the Company and its subsidiaries for distributions or selling to end users. In addition, there is another group of customers who are end users such as people, patients, pet owner, livestock entrepreneurs, farmers, etc. They ordered the products directly from the Company and its subsidiaries through the sales team and through online channels using social networks such as the website www.interpharmastore.com, Facebook, Line@, Instagram, etc. including through the Company’s sales team in a case of independent pharmacies.

The Company and its subsidiaries has appointed Zuellig Pharma Co., Ltd. as a distributor. The Company and its subsidiaries record Zuellig Pharma as an account receivable and bill only to Zuellig Pharma. However, if considering the sales revenue in 2022 - 2025 from customers either directly buying products from the Company and its subsidiaries or buying through Zuellig Pharma, the Company and its subsidiaries have no sales revenue from any single customer with a proportion of more than 30 % of total sales revenue.

In addition, if considering the target customers who are consumers or product end users tending to demand different groups of products of the Company and its subsidiaries, it can be divided by characteristics as follows:

  • Healthcare and Beauty Innovation Products for Human

Healthcare and Anti-aging Products: The target customer group is workers and the elderly who have a medium to high income and care about their health by choosing consume alternative nutrients without medications.

Innovative Beauty Products: The target customer group is teenagers, workers who have medium to high income, and care about their health and a beautiful face and skin.

  • Healthcare Products for Animals: The target customer group is farmers, animal husbandry, livestock operators, feed manufacturers, and pet owners who care about the health, hygiene, and safety of their animals.

Pricing Policy

The products the Company and its subsidiaries sell are both under the Company’s brand and of other product owners that the Company is a distributor or purchaser to resell. In the case of products under the brand of the Company and its subsidiaries, the Company determines the selling price by the cost plus margin method, with the consideration of the cost of goods and related expenses, including other factors such as the market positioning, customer acceptance, purchase demand, packaging size, etc. The standard price list of each product is set in each distribution channel as appropriate. The selling price must be able to compete with other competitors in the market. However, the selling price may be reduced from the standard price to support promotional activities or promotions in various forms, such as price discounts, free gifts, etc. At the same time, the gross profit margin must be maintained and sufficient to cover selling, managing, and operating expenses.

In the case of products that the Company and its subsidiaries are distributors or purchasers for reselling, most product prices are set by the product’s owner or distributor. The price must be reasonable so the Company can profit after deducting the cost of sales and other expenses. Nonetheless, changes in product prices by product owners or distributors will be notified to the Company and its subsidiaries in advance so that the Company can prepare a proper sales plan.

Sale and Distribution Channels

The Company and its subsidiaries distribute all products in the country through 2 distribution channels as follows:

1) Sales Team of the Company and Its Subsidiaries

The Company and its subsidiaries have a sales team who act as a searcher, contacts, builds relationships, and takes care of selling products to various groups of customers, including hospital operators for both humans and animals, beauty salons, pet shops, general companies, modern drugstores, and modern retailers (modern trade). This group of customers will bring the products to sell or provide services to their customers who are end-users. Therefore, this group of customers is our distribution channel. In addition, the Company and its subsidiaries also sell products directly to end users by using the sales team of the Company and its subsidiaries through online channels via social networks such as the website www.interpharmastore.com, Facebook, Line Official Account, TikTok, Shopee, and Lazada.

The Company and its subsidiaries have a sales team with strong knowledge and experience in health products and aesthetic innovations for humans, as well as health products for animals. The sales team is responsible for the entire sales process, from meeting clients to understand their needs, presenting products and their features, providing product samples for trial, and managing sales to various customer groups. Sales personnel receive compensation in the form of a fixed salary and sales incentives or commissions, which are determined based on annual sales targets and are reviewed regularly each year with management approval. The Company and its subsidiaries pay commissions to sales staff in installments, with full payment made only for sales that have been completely collected.

2) Sales Team of Zuellig Pharma

The Company has made the Sales Organization Promotion Agreement with Zuellig Pharma to have Zuellig Pharma be responsible for selling the Company's products in independent drug stores nationwide. Zuellig Pharma provides and hires their sales teams for the products, including Probac 7, PreBS, PreBO, Astacurmin, Multivitamin, YUUU Cleansing Mousse, YUUU Toothpaste, and TS6 - Lady Health, etc., to sell for independent drug stores in Thailand only. The Company will be responsible for marketing and promotion, advertising, and other related expenses.

In addition, the Company and its subsidiaries have public relations channels to provide knowledge about health products through various media such as magazines, brochures, the Company's website, etc. Also, the news of the Company and its subsidiaries can be followed up through online channels, including the websites www.interpharma.co.th and www.mariapetfood.com, Facebook: Interpharma Thailand and Intervetta, Line ID: @interpharma and @intervetta. In addition, the customers can contact for more information at the call center at Tel. no. 0-2634-0225, 08-2422-5999 during 8:30 - 17:00 and via e-mail at cs@interpharma.co.th.

Procurement of Products & Services

Reporting Mode

3117

Procurement (Overall)

The company and its subsidiaries source products for sale to customers, categorized into two types based on the origin of the products

  1. Products under the company's own brand

The company and its subsidiaries outsource production to external manufacturers, both domestically and internationally, from countries such as Taiwan, South Korea, Japan, China, Germany, and France, to manufacture various product types according to the company's specific formulas and production methods. This is done concurrently with the in-house production of some items. The company emphasizes development, innovation, and collaboration with international experts in product manufacturing. The company has a team of experts in nutraceuticals, pharmacology, medical technology, veterinary medicine, and food science who are ready to develop innovative product formulas. For production, the company selects manufacturing facilities that meet quality and manufacturing standards, including GMP and/or ISO, or equivalent or higher standards. These facilities are experienced in the production and sourcing of high-quality raw materials, and maintain strict, clean, and safe production processes to ensure products meet the company's requirements. Furthermore, the company conducts product testing to determine the best results before mass production and distribution to customers.

  1. Products that the company distributes on behalf of other product owners

The company and its subsidiaries have been appointed as distributors of various products from four product owners, namely:

(1) Tensall Bio-Tech Co., Ltd. (Taiwan) for TS6 products.

(2) Dermcare-Vet Pty Ltd. (Australia) for Dermcare products including Dermcare MALASEB, Dermcare PYOHEX, Dermcare Aloveen and Dermcare Natural.

(3) Vet Superior Consultant Co., Ltd. for Dr.Choice, Pet Select and Petinol products.

(4) Big Chemical Co., Ltd. for veterinary pharmaceutical products.

The company introduces new products to its offerings each year, researching innovative products that benefit health and well-being, promote bodily balance, and reduce the risk of various diseases. This caters to the growing consumer trend of health consciousness. Furthermore, the company enhances access to new products by cultivating strong relationships with partners, business networks, and health and beauty experts to continuously exchange and develop new knowledge. This includes participating in seminars, conferences, exhibitions, and events related to health products and beauty innovations, both domestically and internationally, to identify potential business partners and source new products that effectively meet customer needs and current and future market trends.

Raw Material Acquisition (Overall)

The Company and its subsidiaries supply products to distribute to customers, divided into 2 categories by the origin of the product as follows:

  1. Products Under the Company's Brand

The Company and its subsidiaries employ external manufacturers who are not affiliated with the Company, both domestically and abroad, such as Taiwan, South Korea, Japan, China, Germany, France, etc., to be a manufacturer of each type of product according to the product formula and its production, concurrently with the production of certain products at the Company’s own manufacturing facilities. The Company concentrates on developing, inventing, and collaborating with foreign experts to produce many products. The Company has a team of experts in nutraceuticals, pharmacists, medical technicians, veterinarians, and food experts who are ready to develop innovations and invent a product formula in production. The Company has selected factories qualified and standardized in production (Quality and Manufacturing Standard) certified with GMP and/or ISO or other standards equivalent to or higher than these standards. It must be a factory specializing in producing and procuring good quality raw materials with a standardized production that is clean and safe for consumers. These are to obtain products that meet the standards and qualifications required by the Company. In addition, the Company has tested the products before production for further distribution to customers or consumers.

  1. Products Distributed by the Company for Other Product Owners

The Company and its subsidiaries have been appointed as distributors for various products from 4 product owners include (1) Tensall Bio-Tech Co., Ltd. (Taiwan) for TS6, (2) Dermcare-Vet Pty Ltd. (Australia) for Dermcare products include Dermcare MALASEB, Dermcare PYOHEX, Dermcare Aloveen, and Dermcare Natural, (3) Vet Superior Consultant Co., Ltd. for Dr.Choice, Pet Select, and Petinol, and (4) Bic Chemical Co., Ltd. for pet pharmaceutical products.

The Company has launched new products every year. It studies the innovation of new products that are beneficial to health and body, help balance the body, and reduce the risk of various diseases. To meet the needs of consumers who are more health-conscious, the Company also increases the opportunity to access new products by building good relationships with partners, business network, and health and beauty experts in order to exchange and develop new knowledge regularly including participating in seminars, exhibition, or events related to health products and beauty innovations both domestically and internationally. These are to increase the chances of finding partners, or potential business partners, and alternatives for new products that can meet the needs of customers as well as current and future market trends.

Production Policy (Overall)

The Company operates its business in the manufacturing of pharmaceutical and health-related products. The Company recognizes that an efficient, standardized, and well-controlled manufacturing process is a fundamental factor supporting product quality, competitiveness, value creation, and sustainable growth.

The Company has therefore established the Manufacturing Policy as follows:

  1. The Company is committed to conducting its manufacturing operations in compliance with applicable laws, regulations, and requirements of relevant regulatory authorities, both domestically and internationally, including Good Manufacturing Practice (GMP) and other related standards.

  2. The Company emphasizes effective planning and management of manufacturing processes to support business growth, control production costs, and ensure the efficient use of resources.

  3. The Company continuously develops and improves manufacturing processes, technologies, and machinery to enhance operational efficiency, reduce losses, and mitigate risks that may affect product quality.

  4. The Company places importance on in-house manufacturing in conjunction with appropriate outsourcing arrangements, while ensuring that quality control and supervision are applied consistently in accordance with the same standards.

  5. The Company promotes competency development and strict compliance with established procedures among management and employees involved in manufacturing activities to ensure effective, traceable, and auditable production operations.

Production Capacity (Overall)

ItemUnitUnit (if Other)UsedCapacity
Inter Pharma Factory (Ayuthaya)Grain/Seed79.67330,000,000
Inter Pharma Factory (Ayuthaya)-2OthersUnit10037,000,000
Modern Pharma FactoryGrain/Seed92.85800,000,000
Modern Pharma Factory-2OthersKg96.8345,000
Modern Pharma Factory-3OthersCapsule96.151,300,000
Modern Pharma Factory-4Liter9520,000
Modern Pharma Factory-5OthersKg93.75400

Domestic/Overseas Purchase Proportion (Overall)

Raw MaterialSource CountryValue
NoneOther0

Projects Under Construction

Has Projects Under Construction (Y/N)

No

Debentures & Bills of Exchange

Has Debentures (Y/N)

No

Convertible Securities

Has Convertible Securities (Y/N)

No

Contents